Use of Reflux and Ulcer Medications Linked to Kidney Chronic Disease, Stones
Earlier this month, researchers at ASN Kidney Week in Chicago revealed the results from two recent studies on previously unidentified links between the use of reflux and ulcer medications and adverse conditions, such as chronic kidney disease.
While both studies looked into the effects of medications on kidney disease, they came from two different groups: the Catholic University of the Sacred Heart in Rome and the VA Saint Louis Health Care System.
The first study from Rome used data from two studies, which included information on 187,330 patients. The patients had no previous history of kidney stones before taking proton pump inhibitors (PPIs) or histamine receptor-2 (H2) blockers to reduce gastric acid production.
The PPI patients had a 12-year follow-up period, and the H2 blocker patients had a 26-year follow-up period. During this time, 3,245 patients developed symptomatic kidney stones.
The study found a 12 percent higher risk associated with PPIs and a 13 percent risk increase with H2 blockers.
The VA Saint Louis study examined the validity of claims that PPI use increases the chance of developing chronic kidney disease.
Using the Department of Veterans Affairs database, researchers reviewed the data of 152,157 patients who used PPIs or H2 blockers. The researchers found patients who used PPIs had a 30 percent or higher risk of developing chronic kidney disease compared to those who used H2 blockers.
The studies concluded that more information was necessary to make any solid recommendations regarding the use of these medications in regards to kidney health and protection.
End-stage Chronic Kidney Disease Might Qualify You for Disability Benefits
The Disability Help Group can help you determine if your type of kidney impairment qualifies you for Social Security disability benefits. We can also help you file for benefits or appeal a benefits denial.
Call us at 800-800-2009 to schedule a free consultation with our disability advocates.